Xponance LLC Purchases 14,848 Shares of Boston Scientific Corporation $BSX

Xponance LLC lifted its position in Boston Scientific Corporation (NYSE:BSX) by 6.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 262,902 shares of the medical equipment provider’s stock after buying an additional 14,848 shares during the period. Xponance LLC’s holdings in Boston Scientific were worth $25,068,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Parnassus Investments LLC increased its position in shares of Boston Scientific by 14.7% in the 4th quarter. Parnassus Investments LLC now owns 7,899,240 shares of the medical equipment provider’s stock valued at $753,193,000 after buying an additional 1,014,800 shares in the last quarter. Keel Point LLC increased its position in shares of Boston Scientific by 541.0% in the 4th quarter. Keel Point LLC now owns 38,400 shares of the medical equipment provider’s stock valued at $3,661,000 after buying an additional 32,409 shares in the last quarter. IFM Investors Pty Ltd increased its position in shares of Boston Scientific by 4.5% in the 4th quarter. IFM Investors Pty Ltd now owns 324,188 shares of the medical equipment provider’s stock valued at $30,911,000 after buying an additional 14,062 shares in the last quarter. Mattson Financial Services LLC boosted its stake in Boston Scientific by 1.6% in the 4th quarter. Mattson Financial Services LLC now owns 23,459 shares of the medical equipment provider’s stock worth $2,237,000 after purchasing an additional 373 shares during the period. Finally, SmartHarvest Portfolios LLC acquired a new position in Boston Scientific in the 4th quarter worth $527,000. Institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other news, Director Edward J. Ludwig bought 3,580 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Cheryl Pegus bought 1,770 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director directly owned 1,770 shares in the company, valued at $99,987.30. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 9,800 shares of company stock worth $554,012 in the last three months. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on BSX shares. Mizuho reduced their target price on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $77.00 target price on shares of Boston Scientific in a research note on Monday, May 18th. Stifel Nicolaus set a $75.00 target price on shares of Boston Scientific in a research note on Wednesday, May 27th. The Goldman Sachs Group set a $71.00 target price on shares of Boston Scientific in a research note on Thursday, May 28th. Finally, Barclays reduced their target price on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research note on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $85.92.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: BTIG reiterated a bullish view on Boston Scientific, highlighting a low forward P/E and significant upside potential, which may help support the stock after its sharp year-to-date de-rating. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Recent analyst commentary still shows broad Wall Street support, with several buy ratings and price targets well above the current trading range, suggesting some investors see the selloff as overdone.
• Neutral Sentiment: Boston Scientific’s Q1 results beat estimates slightly, with revenue up 11.6% year over year, but the market appears more focused on forward guidance and segment-level growth trends than the last quarter’s results.
• Neutral Sentiment: Erste Group trimmed FY2026 and FY2027 EPS estimates only modestly, signaling little change to the core earnings outlook, though the revisions add to the cautious tone around near-term expectations.
• Negative Sentiment: The stock has been sliding after a guidance reduction and renewed scrutiny over slower growth in important businesses, including WATCHMAN and ablation technologies, which is weighing on investor confidence. Boston Scientific Stock (BSX) Opinions on Recent Stock Decline
• Negative Sentiment: A recent market update showed BSX declined again in the latest session, reinforcing the bearish momentum that has followed the guidance-related selloff. Boston Scientific (BSX) Stock Moves -1.27%: What You Should Know

Boston Scientific Trading Down 2.3%

Boston Scientific stock opened at $47.22 on Friday. The firm has a 50-day moving average of $56.68 and a 200-day moving average of $75.14. Boston Scientific Corporation has a one year low of $46.91 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The company has a market cap of $70.18 billion, a price-to-earnings ratio of 19.76, a P/E/G ratio of 0.91 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the prior year, the business posted $0.75 EPS. The company’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a stock buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.